These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 2977587

  • 1. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.
    O'Hare MD, Felmingham D, Grüneberg RN.
    Drugs Exp Clin Res; 1988; 14(10):617-9. PubMed ID: 2977587
    [Abstract] [Full Text] [Related]

  • 2. In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial.
    O'Hare MD, Ghosh G, Felmingham D, Grüneberg RN.
    J Antimicrob Chemother; 1990 Feb; 25(2):217-20. PubMed ID: 2139436
    [Abstract] [Full Text] [Related]

  • 3. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    Bartoloni A, Colao MG, Orsi A, Dei R, Giganti E, Parenti F.
    J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
    [Abstract] [Full Text] [Related]

  • 4. Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.
    Maple PA, Hamilton-Miller JM, Brumfitt W.
    J Antimicrob Chemother; 1989 Apr; 23(4):517-25. PubMed ID: 2526111
    [Abstract] [Full Text] [Related]

  • 5. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.
    Rolston KV, Dholakia N, Ho DH, LeBlanc B, Dvorak T, Streeter H.
    J Antimicrob Chemother; 1996 Aug; 38(2):265-9. PubMed ID: 8877541
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
    Shonekan D, Mildvan D, Handwerger S.
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
    [Abstract] [Full Text] [Related]

  • 7. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
    Fajardo Olivares M, Hidalgo Orozco R, Rodríguez Garrido S, Gaona Álvarez C, Sánchez Silos RM, Hernández Rastrollo R, Martínez Tallo E, Cordero Carrasco JL.
    Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
    [Abstract] [Full Text] [Related]

  • 8. Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates.
    Tabe Y, Nakamura A, Igari J.
    J Infect Chemother; 2001 Sep; 7(3):142-7. PubMed ID: 11810575
    [Abstract] [Full Text] [Related]

  • 9. Ramoplanin versus methicillin-resistant Staphylococcus aureus: in vitro experience.
    Brumfitt W, Maple PA, Hamilton-Miller JM.
    Drugs Exp Clin Res; 1990 Sep; 16(8):377-83. PubMed ID: 2097143
    [Abstract] [Full Text] [Related]

  • 10. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers.
    Jones RN, Barry AL, Gardiner RV, Packer RR.
    Diagn Microbiol Infect Dis; 1989 Sep; 12(5):385-94. PubMed ID: 2533050
    [Abstract] [Full Text] [Related]

  • 11. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.
    Lawrence T, Rotstein C, Beam TR, Gorzynski EA, Amsterdam D.
    Antimicrob Agents Chemother; 1993 Apr; 37(4):896-900. PubMed ID: 8494388
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of ramoplanin on staphylococci.
    Francis J, Webster H, Newsom SW.
    Drugs Exp Clin Res; 1990 Apr; 16(9):457-60. PubMed ID: 2100247
    [Abstract] [Full Text] [Related]

  • 13. Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains.
    Bernard L, Vaudaux P, Rohner P, Huggler E, Armanet M, Pittet D, Lew DP, Schrenzel J.
    J Microbiol Methods; 2004 May; 57(2):231-9. PubMed ID: 15063063
    [Abstract] [Full Text] [Related]

  • 14. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.
    Fitzgibbon MM, Rossney AS, O'Connell B.
    J Clin Microbiol; 2007 Oct; 45(10):3263-9. PubMed ID: 17687008
    [Abstract] [Full Text] [Related]

  • 15. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC, Ribou G, Masquelier B.
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [Abstract] [Full Text] [Related]

  • 16. Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates.
    Biavasco F, Vignaroli C, Lazzarini R, Varaldo PE.
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3122-6. PubMed ID: 11036034
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT, Schønheyder H, Pers C, Thomsen VF.
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [Abstract] [Full Text] [Related]

  • 18. Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States.
    Jones RN, Goldstein FW, Zhou XY.
    Antimicrob Agents Chemother; 1991 Mar; 35(3):584-6. PubMed ID: 1828137
    [Abstract] [Full Text] [Related]

  • 19. In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.
    Jones RN, Barry AL.
    Diagn Microbiol Infect Dis; 1989 Mar; 12(3):279-82. PubMed ID: 2507218
    [Abstract] [Full Text] [Related]

  • 20. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species.
    Biavasco F, Giovanetti E, Montanari MP, Lupidi R, Varaldo PE.
    J Antimicrob Chemother; 1991 Jan; 27(1):71-9. PubMed ID: 1828799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.